Received Feb 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPVHIB | DTAP + IPV + HIB (PENTACEL) | SANOFI PASTEUR | 4 | UK370AA | IM / RL |
| DTAPIPVHIB | DTAP + IPV + HIB (PENTACEL) | SANOFI PASTEUR | UNK | UK370A | OT / RL |
reports that only the HIB portion of Pentacel was given on Monday with no adverse event; Pentacel was given on monday and it was mixed with sterile water with no adverse event; Initial information received on 19-Feb-2026 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 15 months old male patient who recieved only the HIB portion of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE [PENTACEL (VERO)] was given on monday with no adverse event and it was mixed with sterile water with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Pneumococcal vaccine conj 15v (CRM197) (Vaxneuvance) for Immunisation; and Influenza vaccine (Influenza vaccine) for Influenza immunisation. On 16-Feb-2026, the patient received a dose of 0.5ml of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE Suspension for injection (lot UK370A and expiry date- 31-MAR-2027), standard strength, frequency-once via intramuscular route in the right thigh for Immunization who received only the HIB portion of DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(VERO)/HIB(PRP/T) VACCINE [PENTACEL (VERO)] was given on monday with no adverse event (single component of a two-component product administered) and and it was mixed with sterile water with no adverse event (product preparation error) (latency-same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Vaxneuvance; Influenza vaccine